Below you will find the posters for the conference.
Please click on the poster image to enlarge.
A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants
Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease
Author: Rasha Abdelsalam Elshenawy, Antimicrobial Resistance Consultant and Senior Lecturer, School of Health, Medicine and Life Sciences, University of Hertfordshire
A Comparison of Two RSV-Associated Medically Attended Lower Respiratory Infection (RSV-MALRI) Definitions in a Phase 2b/3 Trial (CLEVER) Evaluating the Safety and Efficacy of Clesrovimab
Retrospective review of inpatient antipseudomonal treatment using ciprofloxacin, piperacillin-tazobactam and meropenem in accordance with EUCAST criteria within an acute London Trust
Understanding blood culture sampling practices for adult acute care hospital patients with suspected severe infection: preliminary findings from an ethnographic study
Scale and spread of a Metronidazole ‘Go Green’ Intravenous to Oral Switch (IVOST) Grassroots Quality Improvement Initiative in Scotland’s Largest Acute Health Board
A Quality Improvement Initiative to Improve Intravenous Gentamicin Management and Promote a Multidisciplinary Approach to Patient-Centred Care in the Acute Setting
A Pragmatic Quality Improvement ‘Good Enough’ Approach to Measuring and Comparing Carbon-Footprint Savings Associated with ‘Go Green’ Switching from Intravenous to Oral Therapy (IVOST)
Author: Oksana Viltsaniuk, Associate Professor of the Department of Propedeutics of Internal Medicine, National Pirogov Memorial Medical University, Vinnytsya
Author: Rasha Abdelsalam Elshenawy, Antimicrobial Resistance Consultant and Senior Lecturer, School of Health, Medicine and Life Sciences, University of Hertfordshire
Determine the phenotypes of antibiotic resistance of Klebsiella pneumoniae infections in children from 0 to 59 months in health district of Koutiala in Mali from August 2023 to March 2024
Gepotidacin and nitrofurantoin efficacy by baseline uropathogen phenotypes and genotypes (by Clinical and Laboratory Standards Institute [CLSI] criteria) recovered from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections (uUTIs)
Gepotidacin and nitrofurantoin efficacy by baseline uropathogen drug-resistant phenotypes (by European Committee on Antimicrobial Susceptibility Testing [EUCAST] criteria) recovered from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections (uUTI)
